



# **RESTAURATION OF AGE RELATED MOTOR IMPAIRMENT: ROLE OF IGF-1 BASED GENE THERAPY AND MICROGLIAL ACTIVATION.**

**Falomir Lockhart, Eugenia**\*; Millan J; Anesetti-Nelli S; Hereñú, CB y Bellini, MJ. Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP- UNLP-CONICET) \*eugefalomir@gmail.com





# INTRODUCTION

Microglial cells play an important role in healthy and diseased brain removing apoptotic neurons, establishing transient connections with neuronal synapses and producing neurotrophic factors that modulate neurogenesis during embryogenesis and adulthood. These cells are essential for ensuring neuroprotection in the normal and pathological condition of central nervous system as they are an important sources of neurotrophic factors. It has been described that aging reduces the ability of microglia to provide neuroprotection. It is well known that IGF-1 plays a physiological role in neuroprotection. In situations involving cytotoxic damage, the microglia increases the production of IGF-1. Previous studies of our

group described that intracerebroventricular (ICV) IGF-1 gene therapy induced a significant improvement in motor performance in aged rats.

## **HYPOTHESIS**

WE PROPOSE THAT RESTORATIVE EFFECTS OF IGF-1 ON MOTOR SKILLS COULD BE MEDIATED BY GLIAL CELLS.

## CONCLUSION

Our results suggest that microglia could be involved in the maintenance of motor skills and offer a novel approach for reversing age-associated motor and exploratory performance in rats.

### RESULTS

We demonstrated that IGF-1 restored motor coordination and forelimb grip strength in aged rats (Figura 1). Also, we found that microglia (Iba-1+) cell number was significantly increased for at least 17 days after treatment with IGF-1 (Xm-senil-IGF-I=556.2±30.50 vs Xm-senil-DsRed= 359.9±18.08; p<0.001) (Figura 2), while astrocytes (GFAP+) showed not changes (Figura 3). The analyze of microglial morphology showed that after treatment with IGF-1 there is an increase in the proportion of microglia with a reactive phenotype (Figura 4).









Figure 2: Representative images of Straitum showing immunoreactivity for Iba1. (A) and (A') Immunohistochemistry for Iba1 of control and experimental rat brain slides, respectively. Bars: 50 μm **(B)** Quantification of Iba1+ cells.



cells

 $1ba1^{+}$ 

200





Experimental

Figure 3: Representative images of Straitum **showing immunoreactivity for GFAP. (A)** and (A') Immunohistochemistry for GFAP of control and experimental rat's brain slides, respectively. Bars: 50 μm **(B)** Quantification of GFAP+ cells.



#### **MATERIALS AND METHODS**

Control

cells

GFAP<sup>+</sup>

**Animals:** Aged Sprague-Dawley female rats (28 month) were used. Animals were divided into two groups: Experimental group (E), treated with RAd-IGF-1, and Control group (C) treated with RAd-DsRed.

**Experimental Protocol:** On experimental day -1 (D-1) all the animals were performed for motor tests. On D0, we perform the stereotactic ICV injection with RAd-IGF-1 or RAd-DsRed. On D17, we performed again the motor tests in all the animals to evaluate the motor performance. Finally, all animals were sacrificed on D18 and their brains were removed and processed for IHQ or qRT-PCR analysis.



**Immunohistochemistry:** Immunohistochemistry was carried out on free-floating sections under moderate shaking. Non-contiguous brain slide were selected and processed with Iba1 or GFAP antibodies (diluted 1:1000) and tetraclorhydrate de 3,3-diaminobenzidine (DAB).

#### **MOTOR TESTS**





Performance on a rotating platform

Suspension from a horizontal wire mesh pole

Performance on a wire mesh ramp